Analyses of adverse events and patient‐reported outcomes with the toxicity index in cancer clinical trials
In conclusion, the TI is a useful summary measure that can be applied to a range of adverse event and patient-reported data to maximize the information collected and provide a more accurate and complete account of the tolerability experience. Future research will focus on extending applications of the TI and exploring its use for the design of clinical trials.
Authors
- Reena S. Cecchini (ORCID: https://orcid.org/0000-0002-9075-9357)
- Mourad Tighiouart (ORCID: https://orcid.org/0000-0001-8021-5690)
- Vinícius F. Calsavara (ORCID: https://orcid.org/0000-0003-2332-5863)
- Michael Luu (ORCID: https://orcid.org/0000-0002-7968-7313)
- Ron D. Hays (ORCID: https://orcid.org/0000-0001-6697-907X)
- Márcio A. Diniz (ORCID: https://orcid.org/0000-0002-2427-7843)
- Greg Yothers (ORCID: https://orcid.org/0000-0002-7965-7333)
- N. Lynn Henry (ORCID: https://orcid.org/0000-0002-4771-5930)
- Hanna Bandos (ORCID: https://orcid.org/0000-0003-1798-8054)
- Gillian Gresham (ORCID: https://orcid.org/0000-0001-7142-1230)
- André Rogatko (ORCID: https://orcid.org/0000-0001-8935-8890)
- Sung‐Jin Kim (ORCID: https://orcid.org/0000-0001-6187-6282)
- Patricia A. Ganz (ORCID: https://orcid.org/0000-0002-1841-4143)
Institutions
- Cedars-Sinai Medical Center (US)
- RAND Corporation (US)
- University of California, Los Angeles (US)
- University of Michigan (US)
- UCLA Health (US)
- UPMC Hillman Cancer Center (US)
- Comprehensive Blood & Cancer Center (US)
- University of Pittsburgh Medical Center (US)
- NRG Oncology (US)
- UCLA Jonsson Comprehensive Cancer Center
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1002/cncr.70086
- Citations
- 1
- Primary Topic
- Statistical Methods in Clinical Trials
- Type
- article
- Field-Weighted Citation Impact
- 2.63